Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
30 01 2021
30 01 2021
Historique:
received:
26
09
2019
revised:
07
07
2020
accepted:
03
12
2020
entrez:
31
1
2021
pubmed:
1
2
2021
medline:
9
3
2021
Statut:
ppublish
Résumé
The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030. 16 independent research groups provided model-based disease burden estimates under a range of vaccination coverage scenarios for ten pathogens: hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever. Using standardised demographic data and vaccine coverage, the impact of vaccination programmes was determined by comparing model estimates from a no-vaccination counterfactual scenario with those from a reported and projected vaccination scenario. We present deaths and DALYs averted between 2000 and 2030 by calendar year and by annual birth cohort. We estimate that vaccination of the ten selected pathogens will have averted 69 million (95% credible interval 52-88) deaths between 2000 and 2030, of which 37 million (30-48) were averted between 2000 and 2019. From 2000 to 2019, this represents a 45% (36-58) reduction in deaths compared with the counterfactual scenario of no vaccination. Most of this impact is concentrated in a reduction in mortality among children younger than 5 years (57% reduction [52-66]), most notably from measles. Over the lifetime of birth cohorts born between 2000 and 2030, we predict that 120 million (93-150) deaths will be averted by vaccination, of which 58 million (39-76) are due to measles vaccination and 38 million (25-52) are due to hepatitis B vaccination. We estimate that increases in vaccine coverage and introductions of additional vaccines will result in a 72% (59-81) reduction in lifetime mortality in the 2019 birth cohort. Increases in vaccine coverage and the introduction of new vaccines into LMICs have had a major impact in reducing mortality. These public health gains are predicted to increase in coming decades if progress in increasing coverage is sustained. Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
Sections du résumé
BACKGROUND
The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030.
METHODS
16 independent research groups provided model-based disease burden estimates under a range of vaccination coverage scenarios for ten pathogens: hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever. Using standardised demographic data and vaccine coverage, the impact of vaccination programmes was determined by comparing model estimates from a no-vaccination counterfactual scenario with those from a reported and projected vaccination scenario. We present deaths and DALYs averted between 2000 and 2030 by calendar year and by annual birth cohort.
FINDINGS
We estimate that vaccination of the ten selected pathogens will have averted 69 million (95% credible interval 52-88) deaths between 2000 and 2030, of which 37 million (30-48) were averted between 2000 and 2019. From 2000 to 2019, this represents a 45% (36-58) reduction in deaths compared with the counterfactual scenario of no vaccination. Most of this impact is concentrated in a reduction in mortality among children younger than 5 years (57% reduction [52-66]), most notably from measles. Over the lifetime of birth cohorts born between 2000 and 2030, we predict that 120 million (93-150) deaths will be averted by vaccination, of which 58 million (39-76) are due to measles vaccination and 38 million (25-52) are due to hepatitis B vaccination. We estimate that increases in vaccine coverage and introductions of additional vaccines will result in a 72% (59-81) reduction in lifetime mortality in the 2019 birth cohort.
INTERPRETATION
Increases in vaccine coverage and the introduction of new vaccines into LMICs have had a major impact in reducing mortality. These public health gains are predicted to increase in coming decades if progress in increasing coverage is sustained.
FUNDING
Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
Identifiants
pubmed: 33516338
pii: S0140-6736(20)32657-X
doi: 10.1016/S0140-6736(20)32657-X
pmc: PMC7846814
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-408Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R024855/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Infect Dis. 2016 May;16(5):592-598
pubmed: 26873665
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Hum Vaccin Immunother. 2018 Jul 3;14(7):1599-1609
pubmed: 29617183
Optometry. 2009 Jan;80(1):36-43
pubmed: 19111256
Bull World Health Organ. 2008 Feb;86(2):140-6
pubmed: 18297169
Lancet. 2019 May 4;393(10183):1843-1855
pubmed: 30961907
MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352-5
pubmed: 24759657
Health Aff (Millwood). 2016 Feb;35(2):199-207
pubmed: 26858370
JAMA. 2007 Nov 14;298(18):2155-63
pubmed: 18000199
Lancet Glob Health. 2019 Apr;7(4):e472-e481
pubmed: 30797735
Vaccine. 2012 Dec 17;31(1):96-108
pubmed: 23142307
Vaccine. 2013 Apr 18;31 Suppl 2:B61-72
pubmed: 23598494
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2743-7
pubmed: 21893535
World Health Stat Q. 1988;41(2):59-63
pubmed: 3176515
J Infect Dis. 2014 Nov 1;210 Suppl 1:S514-22
pubmed: 25316875
Vaccine. 2000 Oct 15;19(4-5):385-6
pubmed: 11027798
Int J Epidemiol. 2005 Dec;34(6):1329-39
pubmed: 16249217
Hum Vaccin Immunother. 2019;15(6):1215-1227
pubmed: 30735087
Curr Opin Infect Dis. 2019 Oct;32(5):435-444
pubmed: 31305493